Phase 3 Clinical Trial of Teriparatide in Japan

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy of teriparatide based on measurements of bone mineral density at lumbar spine

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Teriparatide

Criteria

Inclusion Criteria:

• Japanese patients diagnosed with osteoporosis

• Aged 55 or older

• Patients who are at high risk for fracture

Exclusion Criteria:

• History of metabolic bone disorders other than primary osteoporosis

• History of malignant neoplasm in the 5 years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated.

• Severe or chronically disabling conditions other than osteoporosis